What is Citius Oncology, Inc.'s price / book?

Citius Oncology, Inc. (CTOR) reported price / book of 1.6× in Q1 2026.

How has Citius Oncology, Inc.'s price / book changed year-over-year?

Citius Oncology, Inc.'s price / book decreased by 16.9% year-over-year, from 1.9× to 1.6×.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Citius Oncology, Inc. CTOR Price / book

Price / book at other companies

Merck & Co.MRK

6.5×+1.8×

Delcath SystemsDCTH

2.9×-2.4×

Iovance Biotherapeutics, Inc.IOVA

2×+0.6×

Cullinan Therapeutics, Inc.CGEM

1.5×+0.3×

ImmunomeIMNM

4.2×+2.3×

Arcus BiosciencesRCUS

5.2×+3.6×

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

market cap/total stockholders equity=1.6×

Based on the most recent quarter.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s price / book?: Citius Oncology, Inc. (CTOR) reported price / book of 1.6× in Q1 2026.
How has Citius Oncology, Inc.'s price / book changed year-over-year?: Citius Oncology, Inc.'s price / book decreased by 16.9% year-over-year, from 1.9× to 1.6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.